Bill caps insulin copays at $35 and helps uninsured people.
S. 4189 — INSULIN Act of 2026 · Filed by Jeanne Shaheen (D-NH) · 28 cosponsors · Introduced Mar 25, 2026 · Reported out
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
Starting in 2028, people with health plans pay no more than $35 for insulin. They skip some paperwork too. The bill gives money to help people without health plans buy insulin in ten states. It sets up a hotline and resource center for them. The bill speeds up approval of generic and biosimilar insulin.
Who it affects
People with health plans pay less for insulin. People without health plans in ten states get help buying insulin. Makers of generic and biosimilar insulin get faster approval.
One thing to notice
The $35 copay covers only certain insulin products that health plans pick. Help for people without health plans lasts five years in ten states only.
From the analysis of the bill text, linked under Primary records below.
Where it stands
28 cosponsors: 14 Republicans, 13 Democrats, 1 Independents.
- Mar 25, 2026 — Introduced · Congress.gov: “Introduced in Senate”
- Mar 25, 2026 — Referred to Senate Committee on Health, Education, Labor, and Pensions · Congress.gov: “Read twice and referred to the Committee on Health, Education, Labor, and Pensions”
- Jul 22, 2026 — Reported out of committee · Congress.gov: “Committee on Health, Education, Labor, and Pensions. Ordered to be reported with an amendment in the nature…”
Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.
Money around this bill
8 groups reported lobbying about this bill. They filed 8 reports from Jun 2026 to Jun 2026.
Those reports show $4,462,567 in lobbying spending. Each report lists about 14 bills. So that money was not all for this bill.
More groups named this bill than 88% of bills with any report.
Jeanne Shaheen, who sponsored the bill, received $-12,050 from PACs for the 2026 election.
- Pharmaceutical Care Management Association — $3,282,990 in 1 report
- Johns Hopkins University — $350,000 in 1 report
- Highmark Inc — $230,000 in 1 report
- League of Conservation Voters — $230,000 in 1 report
- Breakthrough T1d (formerly Known As Jdrf Intl.) — $220,000 in 1 report
Lobbying is legal. These reports show who lobbied about this bill, not what changed.
Words to know
- copay — Money a person pays when they pick up medicine at the pharmacy.
- biosimilar — A medicine made from living cells that works like an existing medicine.
- generic — A medicine with the same active ingredient as a brand-name medicine but costs less.
- lobbying — Trying to influence lawmakers about a bill. Companies and groups pay people to do this.
- PACs — Groups that collect money and give it to candidates for office.
- sponsored — To sponsor a bill is to introduce it in Congress and put your name on it.
How this was measured
Analysis — Quorum's AI read the bill text published by Congress.gov (26,163 characters) on Jul 23, 2026. Section numbers in the findings refer to that text, linked below; transparency and hidden-provision scores are compared against the median of 14,206 analysed bills.
Status and sponsors — Congress.gov's bill record — actions, committee referrals and cosponsors — loaded nightly. The timeline shows status changes, not every procedural action.
Money — Senate Lobbying Disclosure Act filings whose specific-issue field names this bill for quarters ending Jun 2026 to Jun 2026. A filing's amount is reported whole beside the median number of bills a filing names; it is never divided across them. PAC receipts are FEC-reported contributions to the sponsor's candidate committee in the 2026 cycle.
As of — lobbying records through Jul 20, 2026 · page rendered 2026-09-17.
“Bill caps insulin copays at $35 and helps uninsured people.” QuorumCivic. https://share.quorumcivic.app/bill/119/s4189/simple Report an error